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Abstract
Objectives: Faced with the COVID-19 pandemic and its 
impact on the availability and quality of both therapeu-
tic and diagnostic methods, the Belgian authorities have 
decided to launch a procedure for additional evaluation of 
the performance of serological tests offered for sale on the 
national territory. This has been proposed with a double 
aim: (1) an in-depth verification of the analytical and clini-
cal performances presented by the manufacturer and (2) 
an economy of scale in terms of centralized validation for 
all the laboratories using the tests subject to evaluation.
Methods: A retrospective validation study was con-
ducted including the serum of 125 patients in order to 
determine the analytical and clinical performances of 
the LIAISON®SARS-CoV-2 from DiaSorin® detecting anti-
SARS-CoV-2 IgG and to compare its clinical performance 
with the enzyme-linked immunosorbent assay (ELISA) 
test from Euroimmun®, one of the first commercially avail-
able tests allowing the detection of anti-SARS-CoV-2 IgA 
and IgG.
Results: The performances of the LIAISON®SARS-
CoV-2  satisfied all the acceptance criteria and provided 
“real world” analytical and clinical performances very 
close to the ones reported by the manufacturer in its insert 
kit. Comparison between the LIAISON®SARS-CoV-2 and 
the ELISA method did not reveal any difference between 
the two techniques in terms of sensitivities and specifici-
ties regarding the determination of the IgG.
Conclusions: This study reports the validation of the 
LIAISON®SARS-CoV-2 allowing to detect IgG antibodies 
specifically directed against SARS-CoV-2. The analytical 
and clinical performances are excellent, and the automa-
tion of the test offers important rates, ideal for absorbing 
an extension of testing.
Keywords: CLIA; COVID-19; ELISA; SARS-CoV-2.
Introduction
On December 31, 2019, the World Health Organization 
(WHO) was alerted to the appearance of several cases 
of pneumonia of unknown origin in the city of Wuhan 
(China). Few weeks later, the pathogen causing this pneu-
monia was identified: it is a new coronavirus called SARS-
CoV-2, the associated disease being designated by the 
term COVID-19 [1]. Since then, a global health crisis has set 
in and the pandemic continues to grow: As of May 6, the 
virus has already spread to 187 countries and territories 
[2], the number of confirmed cases exceeds 3.6 million and 
the number of deaths worldwide stands at 243,401 [3]. The 
number of cases diagnosed, however, only reflects a frac-
tion of the actual number of infections as a large number 
of countries only test severe cases.
The diagnosis of SARS-CoV-2 infection is essential 
for the control of the epidemic, the establishment of 
protective measures and the therapeutic management 
of patients. The WHO recommends detection of the 
viral genome in respiratory samples for the diagnosis 
COVID-19. However, even if RT-qPCR is considered the 
“gold standard”, many pre-analytical and analytical 
limitations have recently been described. First, it has 
been shown that the sensitivity of this method can vary 
depending on the quality of the sample, the stage but 
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also the severity of the disease, leading to approximately 
20% of false-negative cases [4–7].
Furthermore, access to RT-qPCR tests remains limited. 
Despite significant efforts in Belgium to increase the 
number of RT-qPCR testing, this method will not alone 
cover rapid and massive screening of the population.
Considering the health emergency, many cheaper and 
convenient serological tests have rapidly been developed 
and continue to reach the market. To date, more than 183 
different CE marked tests have been identified, including 
131 rapid tests [8]. The pandemic having impacted both 
the usual distribution chains and the commercial offer, 
the risk of fraud and the release of products of question-
able or fluctuating quality have significantly increased, 
leading to urgent appropriate measures by the competent 
authorities to control the market [9]. In order to improve 
the quality and provide health care professionals with 
clearer information of the current commercial offer, 
the Belgian competent national authority has therefore 
decided to introduce an additional step allowing tests to 
benefit from a specific recommendation. The participa-
tion of the manufacturers to this additional step is on a 
voluntary basis.
Three categories of immunoassays exist and allow, 
depending on the tests, to detect the presence of IgG, IgA 
and IgM in response to a SARS-CoV-2 infection: automated 
CLIA (chemiluminescent immunoassay) tests, ELISA 
(enzyme-linked immunosorbent assay) tests manual or 
automated and finally rapid immunochromatographic 
tests. Many hopes are based on these serological tests 
which could play a complementary diagnostic role to the 
RT-qPCR and help in answering several questions such as 
the deconfinement of patients according to their degree 
of immunity, the discrepancy of the results between CT 
scan and RT-qPCR, the evaluation of individual and col-
lective immunity and allow the carrying out of large-scale 
epidemiological analyses. However, the lack of enough 
documentation of the current comparative studies does 
not allow a proper evaluation of the analytical and clini-
cal performances of these different serological tests and to 
date, a serological reference method is still lacking.
This study carries an important epidemiological 
objective but is also part of the deconfinement strategy led 
by the testing group of the task force deployed in Belgium 
to manage the current health crisis. The validation of 
the CLIA test (LIAISON®SARS-CoV-2 IgG kit, DiaSorin®, 
Saluggia, Italy) described in this study responds to an 
official request made by this group of experts. The CLIA 
test (DiaSorin®), which recently obtained CE marking 
(04/17/2020), has another major advantage: there is 
already a large implementation of LIAISON XL® analyzer 
(DiaSorin®) in Belgium (n = 81), allowing the test to be 
carried out on the whole territory. The choice of automa-
tion is preferable to respond to the large number of testing 
needed in the next weeks.
The main objective of this study is to evaluate and 
compare the clinical performance of the LIAISON®SARS-
CoV-2 IgG kit detecting anti-SARS-CoV-2 IgG with the 
ELISA test (Euroimmun Medizinische Labordiagnos-
tika®, Lübeck, Germany) allowing the detection of anti-
IgA and IgG SARS-CoV-2. This study is also the first 
national validation model described to date and the first 
study to report the performance of the LIAISON®SARS-
CoV-2 IgG kit.
This validation will allow the routine implementation 
of a serological test in all Belgian laboratories by rational-
izing its use for clinical purposes and sparing heavy vali-
dation steps consuming time, samples and reagents.
Materials and methods
Study design
This retrospective study was conducted from April 16 to 20, 2020 
at the clinical biology laboratory of the Iris Sud Hospitals (HIS-IZZ, 
Brussels, Belgium). All the sera (n = 125) originate from blood sam-
ples taken during previous clinical requests for diagnostic purposes 
and were stored in the laboratory serum biobank at ≤− 20 °C. Among 
these 125 samples, 81 samples were included in the specificity analy-
sis. The remaining 44 samples were included in the sensitivity analy-
sis. This study has been approved by the Ethical Committee of the 
HIS-IZZ (ethical agreement number: CEHIS/2020-13).
Population
Blood samples positive for COVID-19  were collected from patients 
with mild, severe or critical infection based on the extent of anomalies 
observed on CT scan: moderate (10%–25%), extensive (25%–50%), 
severe (>50%) or critical >75% and on clinical symptoms (headache, 
fever, fatigue, cough and sore throat, myalgia, shortness of breath or 
digestive signs). Patients were considered positive according to the 
results of the RT-qPCR. The delay between the first onset of symp-
toms and the RT-qPCR is variable but has been estimated at 4 days 
(±1 day) in our cohort.
Sample collection: Blood samples were collected in serum col-
lection tubes (BD Vacutainer SST II advance, BD, Plymouth, UK) 
according to standardized operating procedure. Samples were then 
centrifuged at 3500  rpm (2451 g) for 10  min. Serum was then col-
lected, and samples were analyzed as soon as possible. In case the 
analyses were delayed, samples were aliquoted and stored between 
2 and 8 °C for a maximum of 3 days. If the storage was higher than 
3 days, serum sample were stored at ≤− 20 °C. If samples were stored 
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for a longer period of time at ≤− 20 °C, frozen samples were thawed 
1 h at room temperature on the day of the analysis. Re-thawed sam-
ples are vortexed and centrifuged before the analysis. Sera were not 
inactivated before measuring antibodies.
Analytical procedures
The quantitative analysis of the anti-SARS-CoV-2 IgG antibodies 
directed against the subunits (S1) and (S2) of the virus spike pro-
tein was carried out using the LIAISON®SARS-CoV-2 IgG kit on 
a LIAISON®XL analyzer in accordance with the manufacturer’s 
instructions. On the same day, a semi-quantitative analysis of the 
anti-SARS-CoV-2 IgG antibodies directed against the spike protein 
subunit (S1) was carried out using the ELISA method (Euroimmun 
Medizinische Labordiagnostika®) after specific programming on the 
ETI-Max 3000® controller (DiaSorin®) according to the manufactur-
er’s instructions. For each ELISA plate, a ratio between the extinc-
tion of the serum samples and the calibrator was calculated. The 
interpretation criteria provided by the manufacturers are provided 
in Table 1.
Evaluation of the analytical performances of the 
LIAISON®SARS-CoV-2 IgG kit
Evaluation of the performance was performed in accordance with 
the Clinical and Laboratory Standards Institute (CLSI) EP 15-A3 docu-
ment [10]. The acceptance criteria were defined according to the 
performance reported by the manufacturer and are summarized in 
Table 2.
Trueness: Trueness has been evaluated by comparing the average 
value obtained on 20 replicates of two levels of quality control (QC) 
to the target values indicated by the manufacturer, i.e. <6 AU/mL 
for the low QC level and between 15.0 and 45.0 AU/mL for the high 
QC level.
Precision: Precision has been evaluated by analyzing the repeata-
bility (expressed as intra-run CV) and the reproducibility (expressed 
as inter-run CV) of the method. The two levels of controls were run in 
triplicate for 5 consecutive days.
Limit of blank, detection and quantification: The diluent provided 
by the manufacturer was used as a blank sample to determine the 
limit of blank (LoB), detection (LoD) and quantification (LoQ). The 
LoB has been determined by running the blank sample on three sep-
arate occasions to verify that the results are well <1.0 AU/mL. The 
LoD and the LoQ have been determined by running 30 analyses of the 
blank sample using the following equations according to the SH GTA 
04 document – revision 1 of the COFRAC [11].
 – Limit of detection = mean of the 30 measurements + 3*standard 
deviation
 – Limit of quantification = mean of the 30  measurements +  
10*standard deviation
Linearity assessment: Linearity was evaluated according to CLSI 
EP-06. The patient sample with the highest concentration observed 
during the clinical evaluation (i.e. 148 AU/mL) was run in triplicate 
and then diluted by a factor of 2 on five consecutive dilutions using 
the diluent provided by the manufacturer. Each dilution was then 
run in triplicate.
Evaluation of the carry-over: A sample with a high level of antibod-
ies was run in triplicate (A1, A2 and A3) followed by a negative sample 
also run in triplicate (B1, B2 and B3). The ratio is calculated using the 
following equation: (B1 – B3/A3 – B3) × 100. Carry-over below 1% is 
considered satisfactory and is not linked to significant interference.
Evaluation and comparison of the clinical performances 
of the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®) with the 
ELISA SARS-CoV-2 test system (Euroimmun Medizinische 
Labordiagnostika®)
Assessment of the clinical specificity of the two serological 
assays: Several samples (n = 81) were tested to assess the cross-
reactivity. Seventy-three sera from COVID-19-negative patients but 
who had other viral, bacterial, parasitic or autoimmune patholo-
gies that could be considered as confounding factors were included 
in the study. Two sera from COVID-19-negative patients but positive 
to another strain of coronavirus (i.e. one serum was positive to the 
NL63  strain and one serum was positive to the OC43  strain) were 
analyzed. Sera positive for the following viral, bacterial and infec-
tion from parasite origin were included to assess the possible cross-
reactivity: HBsAg (n = 7), HAV IgM (n = 3), adenovirus (n = 1), HSV IgM 
and CMV IgM (n = 1), IgM CMV (n = 8), IgM parvovirus B19 (n = 5), HIV 
(n = 1), ASLO (antistreptolysin O) (n = 4), anti-Treponema pallidum 
antibody (n = 1), IgG Borrelia (n = 1), IgM Mycoplasma pneumoniae 
(n = 10), Toxoplasma gondii IgM (n = 16). The cross-reactivity of the 
following autoimmune pathologies was also assessed: rheumatoid 
factor (n = 1), anti-TPO antibody (n = 7), RAI (search for irregular 
agglutinins) (n = 4), direct coombs (n = 1). Finally, one serum with a 
high level of total IgM (9.01 g/L) (normal range: 0.40–2.30 g/L), one 
serum with high total IgA (4.47 g/L) (normal range: 0.70–4.00 g/L) 
and six sera from COVID-19-negative healthy subjects with no history 
Table 1: Interpretation criteria of the CLIA LIAISON®SARS-CoV-2 IgG 
kit and of the ELISA method on the ETI-Max 3000® controller.
Test   Result   Interpretation
CLIA method   <12.0 AU/mL   Negative
  Between 12.0 AU/mL 
and <15.0 AU/mL
  Doubtfula
  ≥15.0 AU/mL   Positive
ELISA method   Ratio <0.8   Negative
  Ratio ≥0.8 and <1.1   Doubtful
  Ratio ≥1.1   Positive
aProcedure: For the doubtful sample with the LIAISON®SARS-CoV-2 
IgG kit, the sample must be retested in duplicate. If at least  
two of three results are doubtful, the sample will be positive. 
If two of the results/three are <12.0 AU/mL, the sample will be 
negative.
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of known autoimmune pathologies and without any acute infection 
of viral or bacterial origin were included in the study. In these six 
sera, residues from old viral infections were present: IgG parvovirus 
B19 (n = 1), VCA and IgG CMV (n = 2), IgG HZV and IgG Rubella (n = 2), 
HBV antibody (n = 1). All these samples were collected in 2019 before 
the start of the COVID-19 outbreak and were stored at −20 °C.
Assessment of the clinical sensitivity of the two serological 
assays: A total of 44 sera collected at  ≥14 days since the date of the 
confirmation of the diagnostic by RT-qPCR were analyzed to assess 
the clinical sensitivity.
Statistical analyses
Statistical analyses were carried out using MedCalc version 10.4.0.0 
(MedCalc Software, Ostend, Belgium). Descriptive statistics were 
used to analyze the data. Sensitivity was defined as the proportion 
of correctly identified COVID-19-positive patients who were ini-
tially positive by RT-qPCR SARS-CoV-2 determination in respiratory 
samples. Specificity was defined as the proportion of naive par-
ticipants who were classified as positive as analyzed by one of the 
two methods tested in this study. The clinical performance of the 
LIAISON®SARS-CoV-2 IgG kit (DiaSorin®) and of the ELISA methods 
(Euroimmun Medizinische Labordiagnostika®) was examined using 
receiver operator characteristic (ROC) curves. The ROC area under 
the curve (AUC) was calculated as the fraction true positive and false 
positive determined according to the manufacturer’s cut-off values 
for positive results.
Results
Evaluation of the analytical performances of 
the LIAISON®SARS-CoV-2 IgG kit (DiaSorin®)
Trueness
The low QC level showed a mean value of 0.06 ± 0.01 AU/
mL over the 20 samples tested. The high QC level showed 
a mean value of 30.15 ± 0.86 AU/mL. These results agree 
with the acceptance criteria and are in line with speci-
fications provided by the manufacturer. However, the 
manufacturer does not provide a degree of uncertainty for 
its two QC levels but only reports a range, preventing a 
proper assessment of the trueness. Therefore, when avail-
able, trueness should be estimated with other methods or 
experiments.
Precision
Table 2 summarizes the repeatability and reproducibility 
results. These results agree with the acceptance criteria 
and are in line with the CVs provided by the manufacturer. 
Table 2: Acceptance criteria for the evaluation of the analytical performances of the LIAISON®SARS-CoV-2 IgG kit.
Validation step   Acceptance criteria according to the 
manufacturer performances
  Results
Trueness   Low QC level: <6 AU/mL   Low QC level: 0.06 ± 0.01 AU/mL
  High QC level: between 15.0 and 45.0 AU/mL  High QC level: 30.15 ± 0.86 AU/mL
Precision   Repeatability: a   Repeatability:
  Low QC level: ≤3.3%   Low QC level: 3.4%
  High QC level: ≤5.3%   High QC level: 3.6%
  Reproducibility: a   Reproducibility:
  Low QC level: ≤3.7%   Low QC level: 5.1%
  High QC level: ≤11.1%   High QC level: 4.7%
Limit of blank   Not reported by the manufacturer   0.06 ± 0.03 AU/mL
Limit of detection   3.8 AU/mL   0.11 AU/mL
Limit of quantification   Not reported by the manufacturer   0.24 AU/mL
Linearity   Linear regression   Polynomial regression
Carry-over   Not reported by the manufacturer   0.01%
Specificity   Cut-off of the manufacturer
 ≥ 99%
  Cut-off of the manufacturer
100%
    Adapted cut-off (>6.1 AU/mL)
99%
Sensitivity after 2 weeks   Cut-off of the manufacturer
97%
  Cut-off of the manufacturer
91%
    Adapted cut-off (>6.1 AU/mL)
100%
aThe results refer to the groups of samples investigated and are not guaranteed specifications, as differences may exist between 
laboratories and locations. These have to be considered as indicative values.
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The intra- and inter-run CVs were within the range 
reported by the manufacturer for the two levels of QC, 
except for the reproducibility for the low QC level (3.7% as 
reported by the manufacturer vs. 5.1% as reported by this 
validation study).
Limit of blank, detection and quantification
The LoB, LoD and LoQ are 0.06 ± 0.03 AU/mL, 0.11 AU/mL 
and 0.24 AU/mL, respectively. Only the LoD is reported by 
the manufacturer, i.e. 3.8 AU/mL, and the LoD calculated 
by the user according to the CLSI EP17-A2 document is far 
below this value which is in agreement with the accept-
ance criteria [12].
Linearity
Results from the linearity study are reported in 
Figure  1. A regression analysis for second-order poly-
nomials was performed. The regression equation was: 
y = 37.73 + 1.60 × − 0.006 x2. No statistically significant dif-
ference was observed between the measured and expected 
values (p < 0.001).
Carry-over
The following values have been obtained for the different 
samples and the different runs: A1 = 146 AU/mL, A2 = 140 
AU/mL, A3 = 145 AU/mL, B1 = 0.275 AU/mL, B2 = 0.282 AU/
mL and B3 = 0.291 AU/mL. The carry-over is 0.01%.
Evaluation and comparison of the clinical 
performances of the LIAISON®SARS-CoV-2 
IgG kit (DiaSorin®) with the ELISA SARS-
CoV-2 test system (Euroimmun Medizinische 
Labordiagnostika®)
Among the 125  samples evaluated 2  weeks after the 
RT-qPCR positive detection, and according to manufac-
turer’s cut-off, the LIAISON®SARS-CoV-2 IgG kit identi-
fied 40 true positives and 81 true negatives. Four samples 
were classified as false negative and none as false posi-
tive (Figure 2). On the same cohort, the ELISA SARS-CoV-2 
test identified 42 true positives and 79 true negatives. Two 
samples were false positive, and two samples were false 
negative. The specificity and the sensitivity were 100% 
(95% CI: 95%–100%) and 91% (95% CI: 79%–96%), and 






































p < 0.0001 p < 0.0001
IgG DiaSorin IgG Euroimmun
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Figure 2: LIAISON®SARS-CoV-2 and ELISA SARS-CoV-2 IgG antibody performance at more than 2 weeks after a positive RT-qPCR 
determination (n = 125 samples).
Data distribution obtained for negative and positive samples. Lines represent median values with interquartile range.
6      Tré-Hardy et al.: Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody
98% (95% CI: 91%–99%) and 96% (95% CI: 85%–99%) 
for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-
CoV-2 test system, respectively, using the cut-off provided 
by the manufacturer. The kappa index was 0.93 for the two 
tests.
The cut-offs provided by the ROC curve analyses (i.e. 
>6.1 and >0.708 for the LIAISON®SARS-CoV-2 IgG kit and 
the ELISA SARS-CoV-2 test system, respectively) improve 
the performance of the tests. Among the 125  samples 
tested, the use of these adapted cut-offs permits the 
correct reclassification of the four false-negative cases 
with the LIAISON®SARS-CoV-2 IgG kit to the detriment of 
one false-positive case. For the ELISA SARS-CoV-2 test, the 
use of the adapted cut-offs permitted the correct reclas-
sification of the two false-negative cases to the detriment 
of one false-positive case (n = 3 in total). The specificity 
and sensitivity were 99% (95% CI: 93%–100%) and 100% 
(95% CI: 92%–100%), and 96% (95% CI: 90%–96%) and 
100.0% (95% CI: 92%–100%) (Figure 3) and the kappa 
index was 0.98 and 0.95 for the LIAISON®SARS-CoV-2 IgG 
kit and the ELISA SARS-CoV-2 test system, respectively, 
using the adapted cut-offs. There was no statistically sig-
nificant difference between the two tests in terms of clini-
cal performance (p = 0.493).
Assessment of clinical specificity
From the results obtained above, interference from certain 
antibodies or antigens produced following viral, bacterial 
or parasitic infections or following autoimmune patholo-
gies reveals to be relatively low with a specificity of 99% 
(95% CI: 93%–100%) and 96% (95% CI: 90%–96%) for the 
LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 
test system, respectively, using the adapted cut-offs. Using 
the cut-offs provided by the manufacturers, the specificity 
was 100% (95% CI: 95%–100%) and 98% (95% CI: 91%–
99%), a result not statistically and clinically different from 
the adapted cut-off.
Discussion
This study is the first to describe the analytical and clini-
cal performances of the LIAISON®SARS-CoV-2 IgG kit from 
DiaSorin® in comparison with the ELISA method from 
Euroimmun Medizinische Labordiagnostika®, the first 
ELISA testing that reached the market for the quantita-
tive assessment of IgG and IgA directed against the spike 
protein subunit (S1). Only one study has previously evalu-
ated the analytical performance of another CLIA test, the 
MAGLUMI™ 2000 Plus (New Industries Biomedical Engi-
neering Co®, Shenzhen, China) but this was on a smaller 
cohort of patients and samples and this study did not 
compare the performance of the CLIA assay with another 
test [13]. Also, regardless of the technique used (CLIA vs. 
ELISA), it is important to note that there is a difference in 
terms of antigenic targets. Namely, the DiaSorin® kit pro-
vides an additional antibody detection target with the S2 
protein which is involved in the virus fusion machinery 
IgG DiaSorin




























Figure 3: LIAISON®SARS-CoV-2 and ELISA SARS-CoV-2 IgG antibody performance at more than 2 weeks after a positive RT-qPCR 
determination (n = 125 samples).
The adapted cut-offs were the following: >6.1 for the DiaSorin assay and >0.708 for the Euroimmun assay. ROC curves reported excellent 
specificity and sensitivity of 99% (95% CI: 93-100%) and 100% (95% CI: 92-100%), and 96% (95% CI: 90-96%) and 100.0% (95% CI: 
92-100%) for the LIAISON®SARS-CoV-2 IgG kit and the ELISA SARS-CoV-2 test system, respectively, using the adapted cut-offs.
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while the kit from Euroimmun Medizinische Labordiag-
nostika® only detects the S1 protein.
The analytical and clinical performances of the 
LIAISON®SARS-CoV-2  satisfied all the acceptance cri-
teria and provided “real world” analytical and clini-
cal performances very close to the ones reported by the 
manufacturer in its insert kit with the exception of the 
reproducibility for the low QC level, i.e. 3.7% as reported 
by the manufacturer vs. 5.1% as reported by this valida-
tion study. However, an inter-assay CV around 5% is con-
sidered sufficient. Also, regarding the assessment of the 
trueness, the manufacturer does not provide a degree of 
uncertainty for its two QC levels but only reports a range, 
preventing adequate comparison. Therefore, when avail-
able, trueness should be estimated with other methods or 
experiments. Evaluation of the LoQ has not been deter-
mined using the 20% CV method due to the high reagent 
consumption such an evaluation requires. Comparison 
of this method of LoQ determination with the results 
obtained by the 10*SD method as performed in this study 
has to be done to confirm our results.
Comparison between the LIAISON®SARS-CoV-2 and 
the ELISA method did not reveal any difference between 
the two techniques in terms of sensitivities and specifi-
cities regarding the determination of the IgG. However, 
based on the cut-off provided by the manufacturers, two 
results were considered doubtful with the LIAISON®SARS-
COV-2  while one sample was considered doubtful with 
the ELISA methods. Adaptation of cut-off as determined 
by the ROC curve analyses highly improved the clinical 
performances of the tests from the second week following 
the positive RT-qPCR determination, with a sensitivity of 
100% and a specificity of 99%. In comparison, adapta-
tion of the cut-off for the ELISA SARS-CoV-2 test showed a 
sensitivity of 100% and a specificity of 96% on the same 
set of samples suggesting that, by adapting the cut-off, 
the LIAISON®SARS-CoV-2 shows at least, if not better, per-
formances than the ELISA testing. The results obtained 
during this study confirm previous observation that the 
production of IgG is detectable in symptomatic patients 
from the second week following the positive RT-qPCR 
determination [14]. We recommend each center to reestab-
lish their own cut-off to improve the clinical performance 
and avoid false-negative results. Other studies have found 
significant differences in sensitivity when comparing the 
ELISA SARS-CoV-2 test from Euroimmun Medizinische 
Labordiagnostika® with other ELISA tests. According to 
the study by Lassaunière et al. conducted on 111 patients, 
the Wantai®SARS-CoV-2 test (Wantai Biological Pharmacy 
Enterprise®, Beijing, China), which detects total antibod-
ies, showed a specificity of 100% and a sensitivity of 90% 
while the test from Euroimmun Medizinische Labordiag-
nostika® revealed a specificity of 96% and a sensitivity of 
65% [15].
Specificity of IgG antibody detection in 
samples with known antibodies directed 
against different targets
Using the adapted cut-offs, only one false-positive sample 
(i.e. a sample positive for AgHBs) was detected with the 
LIAISON®SARS-CoV-2  while three false positives were 
reported with the ELISA technique. The sera that resulted 
in a cross-reaction showed anti-TPO antibodies (n = 1), 
anti-HAV IgM (n = 1) and ASLO (n = 1). Other studies 
have also observed false positives with the same ELISA 
method and reported interference with sera positive for 
IgM directed against anti-influenza A, -influenza B, anti-
adenovirus and anti-hCoV-HKU1 [15, 16]. According to 
the cross-reactivity studies described in the insert kit of 
the LIAISON®SARS-CoV-2, three samples out of 168 ana-
lyzed also showed cross-reactivity with samples positive 
for anti-HBV (n = 1), anti-influenza (n = 1) and rheumatoid 
factor (n = 1). Although we have not tested the interfer-
ence potential of anti-influenza A and B antibodies, we 
have observed probable new interference with anti-TPO 
antibodies (n = 1), anti-HAV IgM (n = 1) and ASLO (n = 1). 
Another limitation of our cross-reaction study is related 
to the very low number of antibody positive sera from 
other viruses of the Coronaviridae family. Given the rarity 
of these samples, only antibodies specifically directed 
against the NL63 and OC43 viruses were tested and did not 
show cross-reactivity.
Choice of the technique to determine the 
presence of IgG antibodies and clinical 
relevance
To date, an IgG protection threshold has not yet been 
demonstrated. However, if such a threshold should be 
established soon, the ELISA technique will probably be 
less efficient in determining a protection index as it is a 
semi-quantitative method, but additional data will be nec-
essary to confirm this assumption. However, from a practi-
cal point of view, the LIAISON®SARS-CoV-2 assay offers a 
rate of random access tests of up to 170 tests/h while the 
ELISA technique from Euroimmun Medizinische Labor-
diagnostika® adapted on the ETI-max 3000® controller 
has more limited capacities with less flexible batch work 
and up to 160 tests/day but it integrates the possibility to 
combine the analysis of both IgA and IgG.
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The validation of SARS-CoV-2 serological methods is 
currently crucial to detect patients exposed to the virus 
including asymptomatic patients, to provide missing epi-
demiological data in Belgium and other countries and 
potentially be able to detect a protective IgG threshold 
in the population. Serological testing carried out in the 
population will also be a very useful epidemiological 
information to compare the immunological status of a 
population with other countries and perhaps help in the 
development of a predictive visualization on the evolution 
of the epidemic. Routine use of this technique will also 
allow other serological studies to be carried out based on 
 well-targeted population clusters in the hope of announc-
ing the end of the pandemic when 50%–60% of the popu-
lation have been in contact with the virus [17]. In addition 
to this deconfinement strategy, serological tests will also 
assess the potential effectiveness of vaccine trials and 
antibody-mediated therapies [18, 19].
Conclusions
In conclusion, this study is the first to report the valida-
tion of a new CLIA test, the LIAISON®SARS-CoV-2 from 
DiaSorin® allowing to detect IgG antibodies specifically 
directed against SARS-CoV-2. The analytical and clinical 
performances are excellent, especially after adapting the 
cut-offs of the assays, and the automation of the test offers 
important rates, ideal for absorbing an extension of testing.
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